Compare DOLE & BHVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOLE | BHVN |
|---|---|---|
| Founded | 1851 | 2013 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2021 | 2022 |
| Metric | DOLE | BHVN |
|---|---|---|
| Price | $15.85 | $11.57 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $27.69 |
| AVG Volume (30 Days) | 668.1K | ★ 2.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.13% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.28 | N/A |
| Revenue Next Year | $1.84 | N/A |
| P/E Ratio | $106.21 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.52 | $7.48 |
| 52 Week High | $16.51 | $38.23 |
| Indicator | DOLE | BHVN |
|---|---|---|
| Relative Strength Index (RSI) | 53.72 | 48.58 |
| Support Level | $15.60 | $10.61 |
| Resistance Level | $16.51 | $11.80 |
| Average True Range (ATR) | 0.35 | 0.73 |
| MACD | -0.05 | -0.08 |
| Stochastic Oscillator | 20.76 | 36.44 |
Dole PLC operates in the North American and European markets for fresh fruits and vegetables. The company's segment includes Fresh Fruit; Diversified Fresh Produce - EMEA; Diversified Fresh Produce - Americas and ROW. It generates maximum revenue from the Diversified Fresh Produce - EMEA segment. Diversified Fresh Produce - EMEA segment includes Dole's Irish, Dutch, Spanish, Portuguese, French, Italian, U.K., Swedish, Danish, South African, Eastern European, and Brazilian businesses, the majority of which sell a variety of imported and local fresh fruits and vegetables through retail, wholesale and, in some instances, food service channels across the European marketplace.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.